Projektbeschreibung
Regulatorische T-Zell-Therapien weiterentwickeln
Immunbedingte Krankheiten wie Autoimmunität und chronische Entzündungen stellen eine erhebliche sozioökonomische Belastung dar. Die Behandlung dieser Erkrankungen erfolgt in der Regel mit immunsuppressiven Medikamenten, aber auch regulatorische T-Zellen wurden als vielversprechende Therapie vorgeschlagen. Das EU-finanzierte Projekt RESHAPE zielt darauf ab, die wesentliche Rolle der regulatorischen T-Zellen bei der Homöostase des Immunsystems zu nutzen, indem sie übermäßige Immunreaktionen unterdrücken und die periphere Toleranz aufrechterhalten. Hauptziel ist die Entwicklung neuartiger Therapien auf der Basis regulatorischer T-Zellen und der Nachweis ihrer Wirksamkeit bei der Wiederherstellung des immunologischen Gleichgewichts nach einem klinischen adoptiven Transfer bei Patientinnen und Patienten mit immunologischen Erkrankungen.
Ziel
Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy.
Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments.
Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation.
Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies
Wissenschaftliches Gebiet
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SC1-2018-Single-Stage-RTD
Finanzierungsplan
RIA - Research and Innovation actionKoordinator
10117 Berlin
Deutschland